

Can't find Igalmi? Learn about 4 alternative medications for acute agitation, how they compare, and what to discuss with your healthcare provider.
If your healthcare provider has prescribed Igalmi (Dexmedetomidine sublingual film) for acute agitation but you're having trouble finding it in stock, you're not alone. Igalmi is a specialty medication with limited distribution, and sometimes it's simply unavailable when you need it.
The good news is that there are several well-established alternatives for treating acute agitation associated with schizophrenia and bipolar disorder. In this article, we'll explain what Igalmi is, how it works, and walk through the most common alternatives your provider might consider.
Igalmi is the brand name for Dexmedetomidine sublingual film, made by BioXcel Therapeutics. It was approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
What makes Igalmi unique is its delivery method — it's a thin film placed under the tongue or behind the lower lip that dissolves quickly. It doesn't require an injection, which can be a major advantage in acute agitation situations where a patient may be uncooperative with injections.
Igalmi comes in 120 mcg and 180 mcg strengths and costs approximately $95 to $105 per film without insurance.
Igalmi works by activating alpha-2 adrenergic receptors in the brain. This is a fundamentally different mechanism than most other medications used for acute agitation, which typically work through dopamine or GABA pathways.
By stimulating alpha-2 receptors, Igalmi:
This unique mechanism is why some providers prefer Igalmi — it offers calming without the deep sedation or respiratory risks associated with some alternatives.
If Igalmi isn't available, here are four commonly used alternatives for acute agitation. Each has different pros, cons, and considerations.
Drug class: Typical (first-generation) antipsychotic
How it's given: Intramuscular (IM) injection or oral
How it works: Haloperidol blocks dopamine D2 receptors in the brain, reducing psychotic symptoms and agitation. It has been a go-to medication for acute agitation in emergency departments for decades.
Pros:
Cons:
Drug class: Atypical (second-generation) antipsychotic
How it's given: Intramuscular (IM) injection or oral dissolving tablet
How it works: Olanzapine blocks both dopamine D2 and serotonin 5-HT2A receptors, producing a calming effect. The IM formulation works quickly for acute agitation.
Pros:
Cons:
Drug class: Benzodiazepine
How it's given: Intramuscular (IM) injection, intravenous (IV), or oral
How it works: Lorazepam enhances the effect of GABA, the brain's main inhibitory neurotransmitter, producing rapid sedation and anxiolysis.
Pros:
Cons:
Drug class: Atypical (second-generation) antipsychotic
How it's given: Intramuscular (IM) injection
How it works: Ziprasidone blocks dopamine D2 and serotonin 5-HT2A receptors, similar to Olanzapine, but with a different side effect profile.
Pros:
Cons:
The biggest advantage of Igalmi over these alternatives is its non-injectable delivery (sublingual film) and its unique mechanism of action that produces calming without deep sedation or respiratory depression. However, all four alternatives above are well-established, widely available, and effective for acute agitation.
Your healthcare provider will consider factors like:
While Igalmi offers a unique non-invasive option for acute agitation, there are effective alternatives available if you can't find it. Talk to your healthcare provider about which option is best for your specific situation.
If you're still looking for Igalmi, try Medfinder.com to search for availability near you, or check out our other Igalmi guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.